Detection of Tn-antigen in Breast and Prostate Cancer Models by VVL-labeled Red Dye-doped Nanoparticles

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2024 Oct 9

PMID 39382009

Authors

Alejandra Verhassel

Martha Kimani

Kamlesh Gidwani

Jouko Sandholm

Kornelia Gawlitza

Knut Rurack

Pirkko Harkonen

Affiliations

Soon will be listed here.

Abstract

Fluorescence detection of breast and prostate cancer cells expressing Tn-antigen, a tumor marker, with lectin (VVL)-labeled nanoparticles. Breast and prostate cancer cells engineered to express high levels of Tn-antigen and non-engineered controls were incubated with VVL-labeled or unlabeled red dye-doped silica-coated polystyrene nanoparticles. The binding to cells was studied with flow cytometry, confocal microscopy, and electron microscopy. Flow cytometry showed that the binding of VVL-labeled nanoparticles was significantly higher to Tn-antigen-expressing cancer cells than controls. Confocal microscopy demonstrated that particles bound to the cell surface. According to the correlative light and electron microscopy the particles bound mostly as aggregates. VVL-labeled nanoparticles could provide a new tool for the detection of Tn-antigen-expressing breast and prostate cancer cells.

References

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

Gidwani K, Huhtinen K, Kekki H, van Vliet S, Hynninen J, Koivuviita N . A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources. Clin Chem. 2016; 62(10):1390-400. DOI: 10.1373/clinchem.2016.257691. View

Curtis E, Bahrami A, Weikl T, Hall C . Modeling nanoparticle wrapping or translocation in bilayer membranes. Nanoscale. 2015; 7(34):14505-14. PMC: 4686374. DOI: 10.1039/c5nr02255j. View

Behnke T, Mathejczyk J, Brehm R, Wurth C, Ramos Gomes F, Dullin C . Target-specific nanoparticles containing a broad band emissive NIR dye for the sensitive detection and characterization of tumor development. Biomaterials. 2012; 34(1):160-70. DOI: 10.1016/j.biomaterials.2012.09.028. View

Sarma D, Carl P, Climent E, Schneider R, Rurack K . Multifunctional Polystyrene Core/Silica Shell Microparticles with Antifouling Properties for Bead-Based Multiplexed and Quantitative Analysis. ACS Appl Mater Interfaces. 2018; 11(1):1321-1334. DOI: 10.1021/acsami.8b10306. View

Li Q, Anver M, Butcher D, Gildersleeve J . Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines. Mol Cancer Ther. 2009; 8(4):971-9. PMC: 2752371. DOI: 10.1158/1535-7163.MCT-08-0934. View

Palladino P, Papi F, Minunni M, Nativi C, Scarano S . Structurally Constrained MUC1-Tn Mimetic Antigen as Template for Molecularly Imprinted Polymers (MIPs): A Promising Tool for Cancer Diagnostics. Chempluschem. 2022; 87(9):e202200068. DOI: 10.1002/cplu.202200068. View

Behnke T, Wurth C, Hoffmann K, Hubner M, Panne U, Resch-Genger U . Encapsulation of hydrophobic dyes in polystyrene micro- and nanoparticles via swelling procedures. J Fluoresc. 2010; 21(3):937-44. DOI: 10.1007/s10895-010-0632-2. View

Ju T, Aryal R, Kudelka M, Wang Y, Cummings R . The Cosmc connection to the Tn antigen in cancer. Cancer Biomark. 2014; 14(1):63-81. PMC: 5808877. DOI: 10.3233/CBM-130375. View

10.

Haab B . Using lectins in biomarker research: addressing the limitations of sensitivity and availability. Proteomics Clin Appl. 2012; 6(7-8):346-50. PMC: 3703587. DOI: 10.1002/prca.201200014. View

11.

Costa A, Campos D, Reis C, Gomes C . Targeting Glycosylation: A New Road for Cancer Drug Discovery. Trends Cancer. 2020; 6(9):757-766. DOI: 10.1016/j.trecan.2020.04.002. View

12.

Vancova M, Nebesarova J . Correlative Fluorescence and Scanning Electron Microscopy of Labelled Core Fucosylated Glycans Using Cryosections Mounted on Carbon-Patterned Glass Slides. PLoS One. 2015; 10(12):e0145034. PMC: 4699470. DOI: 10.1371/journal.pone.0145034. View

13.

Schjoldager K, Narimatsu Y, Joshi H, Clausen H . Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020; 21(12):729-749. DOI: 10.1038/s41580-020-00294-x. View

14.

Matsumoto Y, Kudelka M, Hanes M, Lehoux S, Dutta S, Jones M . Identification of Tn antigen O-GalNAc-expressing glycoproteins in human carcinomas using novel anti-Tn recombinant antibodies. Glycobiology. 2019; 30(5):282-300. PMC: 7175968. DOI: 10.1093/glycob/cwz095. View

15.

Steentoft C, Vakhrushev S, Vester-Christensen M, Schjoldager K, Kong Y, Bennett E . Mining the O-glycoproteome using zinc-finger nuclease-glycoengineered SimpleCell lines. Nat Methods. 2011; 8(11):977-82. DOI: 10.1038/nmeth.1731. View

16.

Dube D, Bertozzi C . Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005; 4(6):477-88. DOI: 10.1038/nrd1751. View

17.

de Boer P, Hoogenboom J, Giepmans B . Correlated light and electron microscopy: ultrastructure lights up!. Nat Methods. 2015; 12(6):503-13. DOI: 10.1038/nmeth.3400. View

18.

El-Baz N, Nunn B, Bates P, OToole M . The Impact of PEGylation on Cellular Uptake and In Vivo Biodistribution of Gold Nanoparticle MRI Contrast Agents. Bioengineering (Basel). 2022; 9(12). PMC: 9774698. DOI: 10.3390/bioengineering9120766. View

19.

Fang Y, Xue J, Gao S, Lu A, Yang D, Jiang H . Cleavable PEGylation: a strategy for overcoming the "PEG dilemma" in efficient drug delivery. Drug Deliv. 2017; 24(sup1):22-32. PMC: 8812578. DOI: 10.1080/10717544.2017.1388451. View

20.

Rees P, Wills J, Brown M, Barnes C, Summers H . The origin of heterogeneous nanoparticle uptake by cells. Nat Commun. 2019; 10(1):2341. PMC: 6538724. DOI: 10.1038/s41467-019-10112-4. View